The p53 pathway in breast cancer
- PMID: 11879567
- PMCID: PMC138723
- DOI: 10.1186/bcr426
The p53 pathway in breast cancer
Abstract
p53 mutation remains the most common genetic change identified in human neoplasia. In breast cancer, p53 mutation is associated with more aggressive disease and worse overall survival. The frequency of mutation in p53 is, however, lower in breast cancer than in other solid tumours. Changes, both genetic and epigenetic, have been identified in regulators of p53 activity and in some downstream transcriptional targets of p53 in breast cancers that express wild-type p53. Molecular pathological analysis of the structure and expression of constituents of the p53 pathway is likely to have value in diagnosis, in prognostic assessment and, ultimately, in treatment of breast cancer.
Figures
References
-
- el-Deiry WS. Regulation of p53 downstream genes. Semin Cancer Biol. 1998;8:345–357. - PubMed
-
- Sigal A, Rotter V. Oncogenic mutations of the p53 tumor suppressor: The demons of the guardian of the genome. Cancer Res. 2000;60:6788–6793. - PubMed
-
- Hussain SP, Harris CC. Molecular epidemiology and carcino-genesis: endogenous and exogenous carcinogens. Mutat Res. 2000;462:311–322. - PubMed
-
- Malkin D, Li FP, Strong LC, Fraumeni JF, Jr, Nelson CE, Kim DH, Kassel J, Gryka MA, Bischoff FZ, Tainsky MA, Friend SH. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science. 1990;250:1233–1238. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous
